Roth Capital Partners Facilitates CapsoVision’s $27.5 Million IPO

Roth Capital Partners, a leading investment bank, has successfully acted as joint book-running manager for CapsoVision, Inc.’s initial public offering (IPO), raising approximately $27.5 million. CapsoVision, a commercial-stage medical technology company specializing in AI-powered capsule endoscopy solutions, offered 5,500,000 shares of common stock at $5.00 per share. The shares commenced trading on the Nasdaq Capital Market under the ticker symbol ‘CV’ on July 2, 2025. This IPO not only underscores the growing investor interest in innovative medical technologies but also highlights Roth Capital Partners’ expertise in facilitating significant financial milestones for growth-oriented companies.

The offering included an additional option for underwriters to purchase up to 825,000 shares at the IPO price within 30 days, potentially increasing the total proceeds. This move is indicative of the confidence in CapsoVision’s market potential and its AI-driven solutions in the medical technology sector. The successful IPO is a testament to the company’s innovative approach to healthcare and its ability to attract substantial investment, paving the way for future growth and development in the field of capsule endoscopy.

For more details on the offering, visit https://ibn.fm/D3xFn. This development is significant as it represents a major financial achievement for CapsoVision and showcases the vital role of investment banks like Roth Capital Partners in bringing cutting-edge medical technologies to the forefront of the healthcare industry.

This news story relied on content distributed by None. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Roth Capital Partners Facilitates CapsoVision’s $27.5 Million IPO.